基础医学与临床 ›› 2014, Vol. 34 ›› Issue (2): 270-273.
• 短篇综述 • 上一篇 下一篇
邹彬镔,石庆之
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
Received:
Revised:
Online:
Published:
摘要： 热休克蛋白90(HSP90)是许多癌基因下游蛋白的分子伴侣，参与多重致癌途径，涉及急性髓细胞白血病（AML) 的发生和不良预后。HSP90抑制剂是当前AML分子靶向治疗研究药物之一，通过抑制HSP90同时实现对多重致癌信号通路的调控发挥抗白血病作用。
关键词: 急性髓细胞白血病, HSP90抑制剂, 抗白血病, 分子靶向治疗
Abstract: Heat shock protein 90 (HSP90) is a molecular chaperone with many oncogenic client which integrates multiple oncogenic pathways, involving the occurrence and poor prognosis in acute myelogenous leukemia (AML).Currently, HSP90 inhibitors are one research drugs of molecular targeted therapies in treating AML, via HSP90 inhibition to realize the regulation of multiple oncogenic pathways at the same time, and play a role of anti-leukemia effect.
Key words: Acute myelogenous leukemia, Heat shock protein 90 inhibitors, anti-leukemia, molecular target therapy
邹彬镔 石庆之. HSP90抑制剂在急性髓细胞白血病治疗中的最新研究进展[J]. 基础医学与临床, 2014, 34(2): 270-273.
/ 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2014/V34/I2/270
